Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | DYRK3 | O43781 | 7/20 | 0.57 |
| ▸ | PIM1 | P11309 | 4/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.57 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.57 |
| ▸ | DYRK2 | Q92630 | 4/20 | 0.57 |
| ▸ | DYRK1B | Q9Y463 | 4/20 | 0.57 |
| ▸ | CSNK2A3 | Q8NEV1 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | CLK3 | P49761 | 1/20 | 0.49 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.49 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30363501 | 1.00 | KDM4E (0.62) | KDM4EDYRK3PIM1CSNK2A2CSNK2B | |
| SCHEMBL30363342 | 0.87 | MAPT (0.57) | KDM4EDYRK3PIM1CSNK2A2CSNK2B | |
| SCHEMBL26095459 | 0.87 | MAPT (0.57) | KDM4EDYRK3PIM1CSNK2A2CSNK2B | |
| SCHEMBL30363461 | 0.86 | KDM4E (0.64) | KDM4EDYRK3PIM1CSNK2A2CSNK2B | |
| SCHEMBL24904263 | 0.86 | KDM4E (0.64) | KDM4EDYRK3PIM1CSNK2A2CSNK2B | |
| SCHEMBL30363474 | 0.83 | KDM4E (0.58) | KDM4EDYRK3PIM1CSNK2A2CSNK2B | |
| SCHEMBL26093545 | 0.83 | KDM4E (0.58) | KDM4EDYRK3PIM1CSNK2A2CSNK2B | |
| SCHEMBL26095105 | 0.79 | KDM4E (0.58) | KDM4EDYRK3PIM1CSNK2A2CSNK2B | |
| SCHEMBL24904266 | 0.79 | KDM4E (0.60) | KDM4EDYRK3PIM1CSNK2A2CSNK2B | |
| SCHEMBL23510493 | 0.78 | CLK1 (0.60) | KDM4EDYRK3PIM1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340538-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2025-11-06 | — | — | US | disclosed |
| WO-2023072969-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-05-04 | — | — | WO | disclosed |
| EP-4173674-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2023-05-03 | — | — | EP | disclosed |
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TONGJI UNIVERSITY (CN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025301-A1 | Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | TNNI3, TNNT2, MKI67 | KDM4E 3429/4885DYRK3 2851/4885PIM1 1850/4885 |
| US-20250340538-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | KDM4E 2980/4885DYRK3 130/4885PIM1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.